Walleye Trading’s Iovance Biotherapeutics IOVA Stock Holding History

Walleye Trading’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,300	Closed	-$22.7K	–	4404
2025 Q4	$22.7K	Buy	+8,300	New	+$19.2K	﹤0.01%	4100
2025 Q1	–	Sell	-35,800	Closed	-$265K	–	4357
2024 Q4	$265K	Buy	+35,800	New	+$332K	﹤0.01%	3072
2024 Q2	–	Sell	-25,500	Closed	-$378K	–	4589
2024 Q1	$378K	Buy	+25,500	New	+$297K	﹤0.01%	2998
2023 Q3	–	Sell	-4,200	Closed	-$29.6K	–	5155
2023 Q2	$29.6K	Buy	+4,200	New	+$30.1K	﹤0.01%	4053
2022 Q1	–	Sell	-18,800	Closed	-$359K	–	5577
2021 Q4	$359K	Buy	18,800 +15,900	+548%	+$350K	﹤0.01%	3289
2021 Q3	$72K	Sell	2,900 -47,800	-94%	-$1.13M	﹤0.01%	4508
2021 Q2	$1.32M	Buy	50,700 +41,600	+457%	+$1.08M	0.01%	1868
2021 Q1	$288K	Buy	+9,100	New	+$377K	﹤0.01%	3263
2020 Q2	–	Sell	-20,000	Closed	-$599K	–	4408
2020 Q1	$599K	Buy	+20,000	New	+$530K	﹤0.01%	1724

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Walleye Trading's IOVA Position: Q2 2026 in Review

Walleye Trading reduced its Iovance Biotherapeutics (IOVA) stake by 28% in Q2 2026, selling an estimated $14.7K and leaving 9,944 shares worth $41.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3629.

Walleye Trading first reported a position in IOVA in Q1 2020 and has held it in 12 quarters since. The position peaked at $431K in Q3 2021. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Walleye Trading held 9,944 shares of Iovance Biotherapeutics worth $41.4K as of Q2 2026.
Walleye Trading sold 3,868 Iovance Biotherapeutics shares in Q2 2026, an estimated $14.7K.
Iovance Biotherapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #3629 holding.
Walleye Trading first reported a position in Iovance Biotherapeutics in Q1 2020 and has held it in 12 quarters since.
Walleye Trading's Iovance Biotherapeutics position peaked at $431K in Q3 2021.
293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.